{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:00:16Z","timestamp":1784865616563,"version":"3.55.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1442,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"British Columbia Cancer Foundation"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000233","name":"Genome BC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000233","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001282","name":"Ovarian Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1093\/annonc\/mdv382","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T02:19:35Z","timestamp":1442283575000},"page":"2367-2374","source":"Crossref","is-referenced-by-count":41,"title":["Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era"],"prefix":"10.1016","volume":"26","author":[{"given":"S.D.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Coukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.H.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv382_bb0010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/emboj.2012.333","article-title":"The cancer antigenome","volume":"32","author":"Heemskerk","year":"2013","journal-title":"EMBO J"},{"key":"10.1093\/annonc\/mdv382_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv382_bb0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv382_bb0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv382_bb0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv382_bb0035","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1038\/srep02650","article-title":"Comprehensive identification of mutational cancer driver genes across 12 tumor types","volume":"3","author":"Tamborero","year":"2013","journal-title":"Sci Rep"},{"key":"10.1093\/annonc\/mdv382_bb0040","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv382_bb0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv382_bb0050","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/gb-2010-11-8-r82","article-title":"Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors","volume":"11","author":"Jones","year":"2010","journal-title":"Genome Biol"},{"key":"10.1093\/annonc\/mdv382_bb0055","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","article-title":"Response and acquired resistance to everolimus in anaplastic thyroid cancer","volume":"371","author":"Wagle","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv382_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2013-0405","article-title":"Molecular tumor board: the University of California-San Diego Moores Cancer Center experience","volume":"19","author":"Schwaederle","year":"2014","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdv382_bb0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ijc.27817","article-title":"Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial","volume":"132","author":"Tran","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdv382_bb0070","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.molonc.2012.02.008","article-title":"The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy","volume":"6","author":"Arnedos","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1093\/annonc\/mdv382_bb0075","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s13058-014-0460-4","article-title":"New concepts in breast cancer genomics and genetics","volume":"16","author":"Goncalves","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0080","doi-asserted-by":"crossref","first-page":"e98293","DOI":"10.1371\/journal.pone.0098293","article-title":"Identification of druggable cancer driver genes amplified across TCGA datasets","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdv382_bb0085","unstructured":"US Food and Drug Administration. FDA.gov.2014. http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm412861.htm (1 August 2015, date last accessed)."},{"key":"10.1093\/annonc\/mdv382_bb0090","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv382_bb0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv382_bb0100","unstructured":"US Food and Drug Administration. FDA.gov.2015. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm436534.htm (15 March 2015, date last accessed)."},{"key":"10.1093\/annonc\/mdv382_bb0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv382_bb0110","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv382_bb0115","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv382_bb0120","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.26574","article-title":"Clinical trial results of the HER-2\/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02","volume":"118","author":"Mittendorf","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv382_bb0125","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-11-1385","article-title":"Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I\/II trial","volume":"17","author":"Brunsvig","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0130","unstructured":"US National Library of Medicine. clinicaltrials.gov\/show\/NCT01322490. 2014. http:\/\/www.clinicaltrials.gov\/show\/NCT01322490 (17 October 2014, date last accessed)."},{"key":"10.1093\/annonc\/mdv382_bb0135","unstructured":"US National Library of Medicine. clinicaltrials.gov\/show\/NCT01579188. 2012. http:\/\/www.clinicaltrials.gov\/show\/NCT01579188 (17 October 2014, date last accessed)."},{"key":"10.1093\/annonc\/mdv382_bb0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imr.12132","article-title":"Exploiting the curative potential of adoptive T-cell therapy for cancer","volume":"257","author":"Hinrichs","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1093\/annonc\/mdv382_bb0145","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0150","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0155","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv382_bb0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","article-title":"How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?","volume":"5","author":"Haabeth","year":"2014","journal-title":"Front Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0165","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.1016\/j.vaccine.2011.07.090","article-title":"A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors","volume":"29","author":"Wick","year":"2011","journal-title":"Vaccine"},{"key":"10.1093\/annonc\/mdv382_bb0170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdv382_bb0175","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-pharmtox-011112-140326","article-title":"Cause and consequence of cancer\/testis antigen activation in cancer","volume":"54","author":"Whitehurst","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1093\/annonc\/mdv382_bb0180","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1054\/bjoc.2000.1291","article-title":"Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours","volume":"83","author":"Jungbluth","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv382_bb0185","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1084\/jem.181.6.2109","article-title":"Identification of an immunodominant peptide of HER-2\/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines","volume":"181","author":"Fisk","year":"1995","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv382_bb0190","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/1078-0432.CCR-14-2777","article-title":"The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3\/CD28-costimulated T cells prepared for adoptive therapy","volume":"21","author":"Zsiros","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0195","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv382_bb0200","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/14712598.5.9.1183","article-title":"Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy","volume":"5","author":"Bendle","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1093\/annonc\/mdv382_bb0205","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.180.1.347","article-title":"Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes","volume":"180","author":"Kawakami","year":"1994","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv382_bb0210","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/eji.1830240340","article-title":"Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes","volume":"24","author":"Wolfel","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0215","doi-asserted-by":"crossref","first-page":"7626","DOI":"10.4049\/jimmunol.177.11.7626","article-title":"Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB\/c mice","volume":"177","author":"Rolla","year":"2006","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0220","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/eji.201242606","article-title":"Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies","volume":"42","author":"Aleksic","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdv382_bb0230","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.1349-7006.2011.02019.x","article-title":"Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)","volume":"102","author":"Klausz","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1093\/annonc\/mdv382_bb0235","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/hum.2012.041","article-title":"Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma","volume":"23","author":"Morgan","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1093\/annonc\/mdv382_bb0240","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv382_bb0245","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1084\/jem.20141308","article-title":"Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity","volume":"211","author":"Duan","year":"2014","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv382_bb0250","first-page":"255","article-title":"Identification of CD8+ T-cell-stimulating antigen genes in cDNA libraries","volume":"156","author":"Mendoza","year":"2001","journal-title":"Methods Mol Biol"},{"key":"10.1093\/annonc\/mdv382_bb0255","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.humimm.2014.03.003","article-title":"T-cell epitope discovery technologies","volume":"75","author":"Sharma","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0260","unstructured":"Cancer Immunity. CancerImmunity.org.2013. http:\/\/www.cancerimmunity.org\/peptide\/mutations (18 October 2014, date last accessed)."},{"key":"10.1093\/annonc\/mdv382_bb0265","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1084\/jem.186.5.785","article-title":"A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma","volume":"186","author":"Mandruzzato","year":"1997","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv382_bb0270","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.183.3.1185","article-title":"A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes","volume":"183","author":"Robbins","year":"1996","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv382_bb0275","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.7652577","article-title":"A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma","volume":"269","author":"Wolfel","year":"1995","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv382_bb0280","first-page":"4078","article-title":"A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma","volume":"61","author":"Echchakir","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0285","first-page":"5785","article-title":"Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene","volume":"59","author":"Chiari","year":"1999","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0290","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/0008-5472.CAN-03-3231","article-title":"CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation","volume":"64","author":"Sharkey","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0295","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.4049\/jimmunol.162.3.1730","article-title":"A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma","volume":"162","author":"Gaudin","year":"1999","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0300","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijc.1298","article-title":"Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens","volume":"93","author":"Linnebacher","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdv382_bb0305","first-page":"3718","article-title":"High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival","volume":"61","author":"Karanikas","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0310","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI488","article-title":"Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia","volume":"101","author":"Yotnda","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdv382_bb0315","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1073\/pnas.0500090102","article-title":"The response of autologous T cells to a human melanoma is dominated by mutated neoantigens","volume":"102","author":"Lennerz","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdv382_bb0320","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2326-6066.CIR-13-0227","article-title":"HLA-binding properties of tumor neoepitopes in humans","volume":"2","author":"Fritsch","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1093\/annonc\/mdv382_bb0325","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv382_bb0330","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv382_bb0335","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.4049\/jimmunol.172.4.2324","article-title":"The impact of self-tolerance on the polyclonal CD8+ T cell repertoire","volume":"172","author":"Kessels","year":"2004","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0340","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4161\/onci.21285","article-title":"Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment","volume":"1","author":"Bos","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdv382_bb0345","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/gm396","article-title":"Derivation of HLA types from shotgun sequence datasets","volume":"4","author":"Warren","year":"2012","journal-title":"Genome Med"},{"key":"10.1093\/annonc\/mdv382_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2011.09.010","article-title":"Machine learning competition in immunology\u2014prediction of HLA class I binding peptides","volume":"374","author":"Zhang","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1093\/annonc\/mdv382_bb0355","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.4049\/jimmunol.153.12.5586","article-title":"The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes","volume":"153","author":"Sette","year":"1994","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0360","doi-asserted-by":"crossref","first-page":"e28836","DOI":"10.4161\/onci.28836","article-title":"High sensitivity of cancer exome-based CD8T cell neo-antigen identification","volume":"3","author":"van Buuren","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdv382_bb0365","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.immunol.17.1.51","article-title":"Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses","volume":"17","author":"Yewdell","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0370","doi-asserted-by":"crossref","first-page":"7890","DOI":"10.4049\/jimmunol.178.12.7890","article-title":"A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection","volume":"178","author":"Assarsson","year":"2007","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdv382_bb0375","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00251-005-0781-7","article-title":"The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage","volume":"57","author":"Nielsen","year":"2005","journal-title":"Immunogenetics"},{"key":"10.1093\/annonc\/mdv382_bb0380","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00018-005-4528-2","article-title":"Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding","volume":"62","author":"Tenzer","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1093\/annonc\/mdv382_bb0385","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jim.2010.07.003","article-title":"An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies","volume":"360","author":"Nielsen","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1093\/annonc\/mdv382_bb0390","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv382_bb0395","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/path.4105","article-title":"Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease","volume":"229","author":"Castellarin","year":"2013","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdv382_bb0400","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/1078-0432.CCR-13-2147","article-title":"Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer","volume":"20","author":"Wick","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0405","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv382_bb0410","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"21","author":"Linnemann","year":"2015","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdv382_bb0415","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown","year":"2014","journal-title":"Genome Res"},{"key":"10.1093\/annonc\/mdv382_bb0420","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer","volume":"21","author":"van Gool","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0425","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdv382_bb0430","doi-asserted-by":"crossref","first-page":"e27817","DOI":"10.4161\/onci.27817","article-title":"Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy","volume":"3","author":"Champiat","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdv382_bb0435","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv382_bb0440","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ccell.2014.12.004","article-title":"Biomarkers in cancer immunotherapy","volume":"27","author":"Schumacher","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdv382_bb0445","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv382_bb0450","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv382_bb0455","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0460","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv382_bb0465","unstructured":"US National Library of Medicine. clinicaltrials.gov\/show\/NCT02035956. 2014. http:\/\/www.clinicaltrials.gov\/show\/NCT02035956 (18 October 2014, date last accessed)."},{"key":"10.1093\/annonc\/mdv382_bb0470","unstructured":"US National Library of Medicine. clinicaltrials.gov\/ct2\/show\/NCT01970358. 2014. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01970358 (18 October 2014, date last accessed)."},{"key":"10.1093\/annonc\/mdv382_bb0475","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv382_bb0480","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdv382_bb0485","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","article-title":"Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions","volume":"20","author":"Lu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv382_bb0490","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1002\/ijc.22584","article-title":"Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck","volume":"120","author":"Ito","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdv382_bb0495","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<784::AID-IJC14>3.0.CO;2-9","article-title":"Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation","volume":"72","author":"Gjertsen","year":"1997","journal-title":"Int J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935714X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935714X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/12\/2367\/617725\/mdv382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T03:07:55Z","timestamp":1691982475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341935714X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":98,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S092375341935714X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv382","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}